May 13 (Reuters) - Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.5 USD | +0.81% | -3.05% | +15.15% |
05-31 | Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival | RE |
05-31 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.15% | 318B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck stops skin cancer combination therapy testing in late-stage study